Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti–tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study was to assess se...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Rabinowitz, Keren Masha, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, Golan, Maya Aharoni, Shachar, Eyal, Ben-Horin, Shomron, Perets, Tsachi-Tsadok, Ben Zvi, Haim, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Navon, Michal, Krugliak, Noy, Werbner, Michal, Alter, Joel, Dessau, Moshe, Gal-Tanamy, Meital, Freund, Natalia T., Cohen, Dani, Dotan, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552587/
https://www.ncbi.nlm.nih.gov/pubmed/34717923
http://dx.doi.org/10.1053/j.gastro.2021.10.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552587/
https://www.ncbi.nlm.nih.gov/pubmed/34717923
http://dx.doi.org/10.1053/j.gastro.2021.10.029

Ejemplares similares